Procter & Gamble Health Upgraded to 'Hold' by MarketsMOJO, Despite Poor Long-Term Growth

Procter & Gamble Health, a midcap pharmaceutical company, has recently been upgraded to a 'Hold' by MarketsMOJO. This decision is based on the company's high management efficiency, with a ROE of 25.87%, and a low Debt to Equity ratio of 0 times. The stock is also currently in a Mildly Bullish range, with technical indicators such as MACD, Bollinger Band, and KST showing a bullish trend.
However, the company has shown poor long-term growth, with only a 5.79% annual growth in Net Sales and 17.91% in Operating profit over the last 5 years. In addition, the recent results for March 2024 have been negative, with a -21.3% decrease in PAT(Q) and a -17.82% decrease in PBT LESS OI(Q). The DEBTORS TURNOVER RATIO(HY) is also at its lowest at 9.11 times.

With a ROE of 26.6, the stock is currently trading at a Very Expensive valuation with a 10.8 Price to Book Value. However, it is still trading at a discount compared to its average historical valuations. In the past year, the stock has generated a return of -1.61%, while its profits have fallen by -11.1%. On the positive side, the company has a high dividend yield of 4.8 at the current price.

Overall, Procter & Gamble Health has shown below par performance in both the long term and near term. It has underperformed the BSE 500 in the last 3 years, 1 year, and 3 months. Investors should carefully consider these factors before making any investment decisions on this midcap pharmaceutical company.